This article first appeared on GuruFocus.

Exagen Inc (NASDAQ:XGN) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $16.90 million, and the earnings are expected to come in at -$0.16 per share. The full year 2025's revenue is expected to be $67.49 million and the earnings are expected to be -$0.66 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 6 Warning Signs with XGN.

Is XGN fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Exagen Inc (NASDAQ:XGN) have increased from $67.26 million to $67.49 million for the full year 2025 and from $76.42 million to $77.44 million for 2026 over the past 90 days. Earnings estimates have improved from -$0.68 per share to -$0.66 per share for 2025 and from -$0.40 per share to -$0.35 per share for 2026 over the same period.

In the previous quarter ending on June 30, 2025, Exagen Inc's (NASDAQ:XGN) actual revenue was $17.20 million, which beat analysts' revenue expectations of $16.30 million by 5.53%. Exagen Inc's (NASDAQ:XGN) actual earnings were -$0.21 per share, which missed analysts' earnings expectations of -$0.146 per share by -43.84%. After releasing the results, Exagen Inc (NASDAQ:XGN) was up by 14.34% in one day.

Based on the one-year price targets offered by 7 analysts, the average target price for Exagen Inc (NASDAQ:XGN) is $13.14 with a high estimate of $18.00 and a low estimate of $10.00. The average target implies an upside of 12.62% from the current price of $11.67.

Based on GuruFocus estimates, the estimated GF Value for Exagen Inc (NASDAQ:XGN) in one year is $3.45, suggesting a downside of -70.44% from the current price of $11.67.

Based on the consensus recommendation from 8 brokerage firms, Exagen Inc's (NASDAQ:XGN) average brokerage recommendation is currently 1.8, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.